Graveoline (WZY25), 5-methoxy-N, N-dimethyltryptamine (WZY26), dehydroevodiamine (WZY27), and goshuyuamide II (WZY21) were identified as lead molecules for targeting AD-related core targets (AR, SLC6A4, PTGS2, and SRC, respectively). This evidence concerns the gene SLC6A4 and Alzheimer disease.